Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma?

被引：0
|
作者：
Sureda, Anna [1 ]
Pavlosky, Astrid [2 ,3 ]
机构：
[1] Univ Barcelona, Inst Catala Oncol LHosp, Clin Haematol Dept, IDIBELL, Barcelona 08908, Spain
[2] Pavlovsky Ctr, Buenos Aires, Argentina
[3] Fundaleu, Haematol Dept, Buenos Aires, Argentina
来源：
LANCET | 2024年 / 404卷 / 10466期
关键词：
D O I：
10.1016/S0140-6736(24)02138-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1899 / 1901
页数：3
相关论文
共 50 条
  • [31] ABCs of ADCs in management of relapsed/refractory diffuse large B-cell lymphoma
    Alderuccio, Juan Pablo
    Sharman, Jeff P.
    BLOOD REVIEWS, 2022, 56
  • [32] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [33] Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
    Matasar, Matthew J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (11.5): : 1327 - 1330
  • [34] The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma
    Rushton, Christopher
    Alcaide, Miguel
    Cheung, Matthew
    Michaud, Neil R.
    Daigle, Scott
    Rys, Ryan N.
    Arthur, Sarah E.
    Zrymiak, Marquisa
    Davidson, Jordan
    Bushell, Kevin R.
    Yu, Stephen
    Jain, Michael D.
    Shepherd, Lois E.
    Marra, Marco A.
    Kuruvilla, John
    Crump, Michael
    Mann, Koren Kathleen
    Assouline, Sarit E.
    Connors, Joseph M.
    Steidl, Christian
    Johnson, Nathalie A.
    Scott, David W.
    Morin, Ryan D.
    BLOOD, 2020, 136
  • [35] Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma
    Ahmed, Gulrayz
    Furqan, Fateeha
    Nasrollahi, Elham
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 705 - 715
  • [36] Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
    Abdulhaq, Haifaa
    Hwang, Andrew
    Mahmood, Omar
    ONCOTARGETS AND THERAPY, 2023, 16 : 617 - 629
  • [37] TREATMENT PREFERENCES AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE UNITED STATES
    Liu, F. F.
    Collacott, H.
    Clarke, H.
    Michaels-Igbokwe, C.
    VALUE IN HEALTH, 2023, 26 (06) : S316 - S316
  • [38] Patient preferences for treatment in relapsed/refractory diffuse large B-cell lymphoma: a discrete choice experiment
    Birch, Kelly
    Snider, Julia T.
    Chiu, Kevin
    Baumgardner, Jim
    Wade, Sally W.
    Shah, Gunjan
    FUTURE ONCOLOGY, 2022, 18 (25) : 2791 - 2804
  • [39] TREATMENT PATTERNS AND COST ANALYSIS AMONG PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
    Nabhan, C.
    Myerscough, C.
    Kish, J.
    Chung, J.
    Chopra, D.
    VALUE IN HEALTH, 2019, 22 : S82 - S82
  • [40] Practice efficiency of treatment with epcoritamab versus glofitamab in relapsed/refractory diffuse large B-cell lymphoma
    Meyer, Kellie
    Huang, Danmeng
    O'Day, Ken
    Lahue, Betsy J.
    Wang, Anthony
    Mutebi, Alex
    Brodkin, Samantha
    Jun, Monika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345